Cellectar BioSciences raises 58 million from warrant exercises and issues new inducement warrants totaling 1048094 shares

Reuters10-11
Cellectar BioSciences raises 58 million from warrant exercises and issues new inducement warrants totaling 1048094 shares

Cellectar BioSciences Inc. entered into inducement offer agreements with certain holders of existing warrants originally issued on October 25, 2022, July 21, 2024, and July 2, 2025. The holders agreed to exercise warrants for cash to purchase 1,048,094 shares of common stock at an exercise price of $5.25 per share. Additionally, holders paid $0.125 per new inducement warrant. The company received approximately $5.8 million in gross proceeds from these transactions, which closed on October 8, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-098725), on October 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment